[Anti-EGFR and radiotherapy]

Area of Science:

• Oncology
• Molecular Biology
• Radiotherapy

Background:

• Epidermal Growth Factor Receptor (EGFR) is a transmembrane protein frequently implicated in epithelial cancer progression.
• EGFR activation triggers intracellular signaling pathways crucial for cell proliferation, apoptosis inhibition, and angiogenesis.

Purpose of the Study:

• To review the mechanisms by which EGFR-targeted therapies enhance the antitumor activity of ionizing radiation.
• To discuss the rationale for combining EGFR inhibitors with radiotherapy in clinical settings.

Main Methods:

• Review of scientific literature discussing EGFR signaling pathways and targeted therapies (monoclonal antibodies, tyrosine-kinase inhibitors).
• Analysis of proposed mechanisms for radiosensitization by EGFR modulation.
• Examination of ongoing clinical trials investigating combined EGFR inhibition and radiotherapy.

Main Results:

• EGFR-targeted agents can block key cancer-promoting pathways activated by EGFR.
• These agents demonstrate potential to enhance the efficacy of ionizing radiation in preclinical and clinical settings.
• Several mechanisms, including improved DNA damage repair, facilitated apoptosis, and inhibited tumor repopulation, are proposed.

Conclusions:

• Targeting EGFR offers a promising strategy to potentiate radiotherapy for epithelial cancers.
• The combination of EGFR inhibitors and radiotherapy is supported by mechanistic data and is under active clinical investigation.
• Further research and clinical trials are essential to optimize combined treatment protocols.